Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals

Share:
Related RIGL
BMO Analysts Initiate Coverage On Rigel Pharma, Seeing 65% Upside
Benzinga's Top Initiations

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL), and raised its price target from $14.00 to $21.00.

Jefferies noted, “RIGL reported 3Q12 earnings. RIGL continues to expect OSKIRA-4 Phase 2b results for fostamatinib (R788) in rheumatoid arthritis by YE2012 and OSKIRA-1-3 results in 1H13. We continue to believe in long-term upside for RIGL shares given the potential for fostamatinib and are increasing our estimates for the higher-than expected Xeljanz (oral competitor) pricing.”

Rigel Pharmaceuticals closed on Tuesday at $8.76.

Latest Ratings for RIGL

DateFirmActionFromTo
Aug 2016BMO CapitalInitiates Coverage onOutperform
Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!